GSK’s travel plans, or lack thereof
GlaxoSmithKline responds to an article in 1"The Pink Sheet" (April 3, 2006, p. 8) discussing international mergers. "The article quotes comments made by Clifford Kalb, VP of Life Sciences at Wood Mackenzie, speculating on future mergers expected in the pharmaceutical industry," GSK notes. "Among those comments, the article references Mr. Kalb as saying that GlaxoSmithKline's CEO 'recently visited the offices of New Jersey Governor Jon Corzine seeking a tax break to relocate the firm's headquarters.' Mr. Kalb's speculation is completely wrong. The company's CEO has not met with Governor Corzine, and GlaxoSmithKline has no intention of moving its headquarters from the UK to the U.S.," GSK says...
You may also be interested in...
Sanofi-Synthelabo's merger with Aventis may be the first in a trend towards the creation of national pharma companies that could include the formation of "Pharma Swiss," according to Wood Mackenzie VP-Life Sciences Clifford Kalb
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."